Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simona Colla

Showing results (61-70 of 91) with videos related to

Pageof 10
Sort By:
Cancer Discovery|July 4, 2012
microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-β signaling in glioblastomaGiannicola Genovese, Ayla Ergun, Sachet A Shukla, et al.
The Lancet. Haematology|February 5, 2024
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 studyAlex Bataller, Guillermo Montalban-Bravo, Alexandre Bazinet, et al.
Oncotarget|March 9, 2018
Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasmsGuillermo Montalban-Bravo, Koichi Takahashi, Keyur Patel, et al.
Nature Communications|November 26, 2021
Hematopoiesis under telomere attrition at the single-cell resolutionNatthakan Thongon, Feiyang Ma, Andrea Santoni, et al.
Blood|November 16, 2006
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1John D Shaughnessy, Fenghuang Zhan, Bart E Burington, et al.
Cancer Research|March 5, 2015
Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancerPiergiorgio Pettazzoni, Andrea Viale, Parantu Shah, et al.
Cancer Cell|July 4, 2017
ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple MyelomaMatteo Marchesini, Yamini Ogoti, Elena Fiorini, et al.
Biorxiv : the Preprint Server for Biology|August 30, 2024
A STAT3 Degrader Demonstrates Pre-clinical Efficacy in Venetoclax resistant Acute Myeloid LeukemiaSamarpana Chakraborty, Claudia Morganti, Bianca Rivera Pena, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 27, 2017
PAF promotes stemness and radioresistance of glioma stem cellsDerrick Sek Tong Ong, Baoli Hu, Yan Wing Ho, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 13, 2021
Telomere dysfunction instigates inflammation in inflammatory bowel diseaseDeepavali Chakravarti, Rumi Lee, Asha S Multani, et al.
Pageof 10

Showing results (61-70 of 91) with videos related to

Sort By:
Pageof 10
Cancer Discovery|July 4, 2012
microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-β signaling in glioblastomaGiannicola Genovese, Ayla Ergun, Sachet A Shukla, et al.
The Lancet. Haematology|February 5, 2024
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 studyAlex Bataller, Guillermo Montalban-Bravo, Alexandre Bazinet, et al.
Oncotarget|March 9, 2018
Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasmsGuillermo Montalban-Bravo, Koichi Takahashi, Keyur Patel, et al.
Nature Communications|November 26, 2021
Hematopoiesis under telomere attrition at the single-cell resolutionNatthakan Thongon, Feiyang Ma, Andrea Santoni, et al.
Blood|November 16, 2006
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1John D Shaughnessy, Fenghuang Zhan, Bart E Burington, et al.
Cancer Research|March 5, 2015
Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancerPiergiorgio Pettazzoni, Andrea Viale, Parantu Shah, et al.
Cancer Cell|July 4, 2017
ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple MyelomaMatteo Marchesini, Yamini Ogoti, Elena Fiorini, et al.
Biorxiv : the Preprint Server for Biology|August 30, 2024
A STAT3 Degrader Demonstrates Pre-clinical Efficacy in Venetoclax resistant Acute Myeloid LeukemiaSamarpana Chakraborty, Claudia Morganti, Bianca Rivera Pena, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 27, 2017
PAF promotes stemness and radioresistance of glioma stem cellsDerrick Sek Tong Ong, Baoli Hu, Yan Wing Ho, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 13, 2021
Telomere dysfunction instigates inflammation in inflammatory bowel diseaseDeepavali Chakravarti, Rumi Lee, Asha S Multani, et al.
Pageof 10